AI Summary
Thinking
Thinking
We reviewed 36 live results for idacio adalimumab and narrowed them down to the 3 options that look most worth comparing first.
The options are Idacio, Idacio (adalimumab) and Idacio (Adalimumab).
Source: Fresenius Kabi (Singapore) Pte Ltd
Description
Idacio is an adalimumab biosimilar registered in Singapore since 2021. It is available as a solution for injection in various formats including pre-filled pens, syringes, and vials (40mg/0.8ml). It is used for the treatment of immune-mediated inflammatory diseases.
Best for
vial-based administration, pen-based injection and HSA-registered treatments
Rate this product
Source: Fresenius Kabi
Description
Idacio is a biosimilar biologic medication containing adalimumab, a TNF-alpha inhibitor used to treat a wide range of inflammatory conditions. These include rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, and plaque psoriasis. The medication is typically provided as a 40 mg/0.8 mL solution for subcutaneous injection, available in formats such as a single-dose pre-filled pen (autoinjector), a pre-filled syringe, or a single-dose vial for pediatric or specific dosing needs. As a biosimilar, it offers a clinically equivalent and often more accessible alternative to the reference product Humira.
Best for
rheumatoid arthritis treatment, psoriasis management, Crohn’s disease patients, biosimilar medication seekers and subcutaneous injection therapy
Rate this product
Source: Fresenius Kabi Philippines, Inc.
Description
Idacio is a citrate-free adalimumab biosimilar biologic medicine manufactured by Fresenius Kabi. Delivered as a 40 mg/0.8 mL solution for subcutaneous injection, it is available in prefilled pen (auto-injector) and prefilled syringe formats. It is indicated for treating chronic inflammatory conditions such as Rheumatoid Arthritis, Psoriatic Arthritis, Crohn’s Disease, and Ulcerative Colitis, providing a highly similar alternative to the reference product Humira.
Best for
rheumatoid arthritis treatment, inflammatory bowel disease therapy, citrate-free injection preference and adalimumab biosimilar therapy
Rate this product
| Compare | #1Idacio | #2Idacio (adalimumab) | #3Idacio (Adalimumab) |
|---|---|---|---|
| Source | Fresenius Kabi (Singapore) Pte Ltd | Fresenius Kabi | Fresenius Kabi Philippines, Inc. |
| Description | Idacio is an adalimumab biosimilar registered in Singapore since 2021. It is available as a solution for injection in various formats including pre-filled pens, syringes, and vials (40mg/0.8ml). It is used for the treatment of immune-mediated inflammatory diseases. | Idacio is a biosimilar biologic medication containing adalimumab, a TNF-alpha inhibitor used to treat a wide range of inflammatory conditions. These include rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, and plaque psoriasis. The medication is typically provided as a 40 mg/0.8 mL solution for subcutaneous injection, available in formats such as a single-dose pre-filled pen (autoinjector), a pre-filled syringe, or a single-dose vial for pediatric or specific dosing needs. As a biosimilar, it offers a clinically equivalent and often more accessible alternative to the reference product Humira. | Idacio is a citrate-free adalimumab biosimilar biologic medicine manufactured by Fresenius Kabi. Delivered as a 40 mg/0.8 mL solution for subcutaneous injection, it is available in prefilled pen (auto-injector) and prefilled syringe formats. It is indicated for treating chronic inflammatory conditions such as Rheumatoid Arthritis, Psoriatic Arthritis, Crohn’s Disease, and Ulcerative Colitis, providing a highly similar alternative to the reference product Humira. |
| Best for | vial-based administration, pen-based injection and HSA-registered treatments | rheumatoid arthritis treatment, psoriasis management, Crohn’s disease patients, biosimilar medication seekers and subcutaneous injection therapy | rheumatoid arthritis treatment, inflammatory bowel disease therapy, citrate-free injection preference and adalimumab biosimilar therapy |
| Action | Fresenius Kabi (Singapore) Pte Ltd | Fresenius Kabi | Fresenius Kabi Philippines, Inc. |
| Rate this product |
"Idacio from Fresenius Kabi (Singapore) Pte Ltd."
TopFind picked this because One of the few biosimilar options that includes a vial format for specific clinical needs.
Note: TopFind AI compiles product and service information for general comparison purposes only.